• Sat. Jun 10th, 2023

Evaxion unveils proprietary genetic adjuvant technologies to


May 25, 2023
  • Evaxion created a genetic adjuvant technologies that boosts the immune responses of viral, bacterial and cancer vaccines
  • Preclinically validated for each DNA and mRNA vaccines, and prepared for clinical testing  
  • Anticipated significant market place prospective for DNA and mRNA vaccines against cancer, viral and bacterial illnesses

COPENHAGEN, Denmark, Could 25, 2023 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology enterprise specializing in the discovery and improvement of AI-powered immunotherapies, these days unveils the technologies behind its novel, proprietary genetic adjuvant created to boost the effectiveness of DNA and mRNA vaccines for infectious illnesses and cancer. 

Newest information from the adjuvant plan had been presented at Evaxion’s reside stream R&ampD Day, Could 25, 2023. 

“We are excited to present this novel genetic adjuvant technologies to the international scientific neighborhood. It boosts Evaxion´s personal DNA technologies and has the prospective to increase the impact of practically any vaccine. We foresee a excellent market place prospective in that this technologies seems to be hugely productive in each DNA and mRNA primarily based vaccines against cancer as nicely as infectious illnesses,” stated Per Norlén, CEO at Evaxion

Evaxion´s novel genetic adjuvant carries the code for CCL19, a molecule identified to attract immune cells, notably antigen presenting cells, and can be encoded into either DNA or mRNA vaccines with the aim of boosting the immune response. 

Newest information show that the genetic adjuvant technologies boosts the antitumor impact in preclinical tumor models, and induces neutralizing antibodies and T-cell responses against each viral and bacterial antigens: 

  • Delivery of DNA or mRNA cancer neoantigen vaccines induced robust neoantigen-distinct T-cell responses and comprehensive antitumor responses
  • Delivery of a COVID-19 T-cell epitope DNA vaccine resulted in a robust and distinct T-cell response and protected against a lethal dose of the virus (90% survival)
  • Delivery of a Neisseria Gonorrhoeae antigen DNA vaccine induced higher antibody titers and distinct T-cell responses towards the bacterial antigens
  • Per Norlén continues, “By encoding the immune-stimulating molecule CCL19 into either DNA or mRNA vaccines, we have demonstrated substantial enhancement of the vaccines effectiveness. We think that this advancement holds immense prospective for vaccine improvement, as it boosts each B cell and T cell immune responses, creating it applicable to a wide variety of vaccines. Developing on the encouraging preclinical benefits, the subsequent step is to validate the technologies in sufferers.” 

    Evaxion aims to bring the genetic adjuvant technologies into clinical trials later this year as element of the customized cancer immunotherapy plan EVX-03.  

    Please go to the Investors section of Evaxion’s web site to access a replay of the R&ampD Day presentations. 

    About Evaxion

    Evaxion Biotech A/S is a pioneering enterprise creating AI-powered immunotherapies. Evaxion’s proprietary and scalable AI technologies decode the human immune technique to uncover and create novel immunotherapies for cancer, bacterial illnesses, and viral infections. Evaxion has a broad pipeline of candidates, which includes 3 customized cancer immunotherapies. It is positioned in Hørsholm, Denmark, with 50 staff listed on the Nasdaq New York stock exchange. For extra data, please go to www.evaxion-biotech.com.

    Forward-hunting statement 
    This announcement consists of forward-hunting statements inside the which means of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of equivalent which means determine forward-hunting statements. Actual benefits could differ materially from these indicated by such forward-hunting statements as a outcome of numerous components, which includes, but not restricted to, dangers associated to: our monetary situation and want for more capital our improvement perform expense and good results of our solution improvement activities and preclinical and clinical trials commercializing any authorized pharmaceutical solution created working with our AI platform technologies, which includes the price and degree of market place acceptance of our solution candidates our dependence on third parties which includes for conduct of clinical testing and solution manufacture our inability to enter into partnerships government regulation protection of our intellectual house rights employee matters and managing development our ADSs and ordinary shares, the effect of international financial, political, legal, compliance, social and organization components, which includes inflation, and the effects on our organization from the worldwide COVID-19 pandemic and the ongoing conflict in the area surrounding Ukraine and Russia and other uncertainties affecting our organization operations and monetary situation. For a additional discussion of these dangers, please refer to the danger components incorporated in our most current Annual Report on Kind 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are out there at www.sec.gov. We do not assume any obligation to update any forward-hunting statements except as expected by law.

    Leave a Reply